MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,953 shares of the biopharmaceutical company’s stock after selling 778 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Alnylam Pharmaceuticals were worth $3,764,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after acquiring an additional 323,206 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $69,292,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Alnylam Pharmaceuticals by 203.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company’s stock valued at $76,195,000 after acquiring an additional 189,128 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after acquiring an additional 185,783 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Alnylam Pharmaceuticals by 30,759.4% during the first quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company’s stock valued at $44,913,000 after purchasing an additional 165,793 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Chardan Capital raised their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Jefferies Financial Group raised their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a “buy” rating in a research report on Monday, July 7th. Finally, Oppenheimer raised Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price objective on the stock in a research report on Monday, August 4th. Twenty-three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $421.28.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Colleen F. Reitan sold 18,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the transaction, the director directly owned 775 shares in the company, valued at $362,390. The trade was a 95.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the transaction, the executive vice president owned 50,121 shares of the company’s stock, valued at approximately $22,718,345.67. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock worth $33,968,256 over the last ninety days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $465.89 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $484.21. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market cap of $61.07 billion, a price-to-earnings ratio of -188.62 and a beta of 0.32. The firm’s fifty day moving average is $401.46 and its two-hundred day moving average is $316.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. During the same quarter in the previous year, the company earned ($0.13) earnings per share. The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.